Persistent Asset Partners’s Intellia Therapeutics NTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$24 Buy
+2
New +$25 ﹤0.01% 780

Other funds holding NTLA

Persistent Asset Partners's NTLA Position: Q3 2026 in Review

Persistent Asset Partners opened a new position in Intellia Therapeutics (NTLA) in Q3 2026: 2 shares worth $24. The stake represents ﹤0.01% of the portfolio and ranks #780 among its holdings.

311 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

  • Persistent Asset Partners held 2 shares of Intellia Therapeutics worth $24 as of Q3 2026.
  • Intellia Therapeutics was a new Persistent Asset Partners position in Q3 2026.
  • Intellia Therapeutics made up ﹤0.01% of Persistent Asset Partners's portfolio in Q3 2026, its #780 holding.
  • 311 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on Persistent Asset Partners's 13F filing for Q3 2026, filed 13 Nov 2026.